Free Trial
NASDAQ:BFRG

Bullfrog AI 11/14/2023 Earnings Report

Bullfrog AI logo
$1.27 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 -0.02 (-1.18%)
As of 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bullfrog AI EPS Results

Actual EPS
-$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bullfrog AI Revenue Results

Actual Revenue
$0.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bullfrog AI Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bullfrog AI's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Bullfrog AI Earnings Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
BFRG - Bullfrog AI Holdings Inc News | Morningstar
See More Bullfrog AI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bullfrog AI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bullfrog AI and other key companies, straight to your email.

About Bullfrog AI

Bullfrog AI (NASDAQ:BFRG) Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

View Bullfrog AI Profile

More Earnings Resources from MarketBeat